Zeshan Ahmed
Eli Lilly and Company
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Zeshan Ahmed.
The Journal of Neuroscience | 2016
Samuel Jackson; Caroline Kerridge; Jane Cooper; Annalisa Cavallini; Benjamin Falcon; Claire V. Cella; Alessia Landi; Philip Szekeres; Tracey K. Murray; Zeshan Ahmed; Michel Goedert; Michael Hutton; Michael J. O'Neill; Suchira Bose
The interneuronal propagation of aggregated tau is believed to play an important role in the pathogenesis of human tauopathies. It requires the uptake of seed-competent tau into cells, seeding of soluble tau in recipient neurons and release of seeded tau into the extracellular space to complete the cycle. At present, it is not known which tau species are seed-competent. Here, we have dissected the molecular characteristics of seed-competent tau species from the TgP301S tau mouse model using various biochemical techniques and assessed their seeding ability in cell and animal models. We found that sucrose gradient fractions from brain lysates seeded cellular tau aggregation only when large (>10 mer) aggregated, hyperphosphorylated (AT8- and AT100-positive) and nitrated tau was present. In contrast, there was no detectable seeding by fractions containing small, oligomeric (<6 mer) tau. Immunodepletion of the large aggregated AT8-positive tau strongly reduced seeding; moreover, fractions containing these species initiated the formation and spreading of filamentous tau pathology in vivo, whereas fractions containing tau monomers and small oligomeric assemblies did not. By electron microscopy, seed-competent sucrose gradient fractions contained aggregated tau species ranging from ring-like structures to small filaments. Together, these findings indicate that a range of filamentous tau aggregates are the major species that underlie the spreading of tau pathology in the P301S transgenic model. SIGNIFICANCE STATEMENT The spread of tau pathology from neuron to neuron is postulated to account for, or at least to contribute to, the overall propagation of tau pathology during the development of human tauopathies including Alzheimers disease. It is therefore important to characterize the native tau species responsible for this process of seeding and pathology spreading. Here, we use several biochemical techniques to dissect the molecular characteristics of native tau protein conformers from TgP301S tau mice and show that seed-competent tau species comprise small fibrils capable of seeding tau pathology in cell and animal models. Characterization of seed-competent tau gives insight into disease mechanisms and therapeutic interventions.
NeuroImage | 2016
Niall Colgan; Bernard Siow; James M. O'Callaghan; Ian F. Harrison; Jack A. Wells; Holly Holmes; Ozama Ismail; Simon Richardson; Daniel C. Alexander; Emily C. Collins; Elizabeth M. C. Fisher; Ross A. Johnson; Adam J. Schwarz; Zeshan Ahmed; Michael J. O'Neill; Tracey K. Murray; Hui Zhang; Mark F. Lythgoe
Increased hyperphosphorylated tau and the formation of intracellular neurofibrillary tangles are associated with the loss of neurons and cognitive decline in Alzheimers disease, and related neurodegenerative conditions. We applied two diffusion models, diffusion tensor imaging (DTI) and neurite orientation dispersion and density imaging (NODDI), to in vivo diffusion magnetic resonance images (dMRI) of a mouse model of human tauopathy (rTg4510) at 8.5 months of age. In grey matter regions with the highest degree of tau burden, microstructural indices provided by both NODDI and DTI discriminated the rTg4510 (TG) animals from wild type (WT) controls; however only the neurite density index (NDI) (the volume fraction that comprises axons or dendrites) from the NODDI model correlated with the histological measurements of the levels of hyperphosphorylated tau protein. Reductions in diffusion directionality were observed when implementing both models in the white matter region of the corpus callosum, with lower fractional anisotropy (DTI) and higher orientation dispersion (NODDI) observed in the TG animals. In comparison to DTI, histological measures of tau pathology were more closely correlated with NODDI parameters in this region. This in vivo dMRI study demonstrates that NODDI identifies potential tissue sources contributing to DTI indices and NODDI may provide greater specificity to pathology in Alzheimers disease.
NeuroImage | 2015
Jack A. Wells; James M. O'Callaghan; Holly Holmes; Nick M. Powell; Ross A. Johnson; Bernard Siow; Francisco Torrealdea; Ozama Ismail; Simon Walker-Samuel; Xavier Golay; Marilena Rega; Simon Richardson; Marc Modat; Manuel Jorge Cardoso; Sebastien Ourselin; Adam J. Schwarz; Zeshan Ahmed; Tracey K. Murray; Michael J. O'Neill; Emily C. Collins; Niall Colgan; Mark F. Lythgoe
As the number of people diagnosed with Alzheimers disease (AD) reaches epidemic proportions, there is an urgent need to develop effective treatment strategies to tackle the social and economic costs of this fatal condition. Dozens of candidate therapeutics are currently being tested in clinical trials, and compounds targeting the aberrant accumulation of tau proteins into neurofibrillary tangles (NFTs) are the focus of substantial current interest. Reliable, translatable biomarkers sensitive to both tau pathology and its modulation by treatment along with animal models that faithfully reflect aspects of the human disease are urgently required. Magnetic resonance imaging (MRI) is well established as a valuable tool for monitoring the structural brain changes that accompany AD progression. However the descent into dementia is not defined by macroscopic brain matter loss alone: non-invasive imaging measurements sensitive to protein accumulation, white matter integrity and cerebral haemodynamics probe distinct aspects of AD pathophysiology and may serve as superior biomarkers for assessing drug efficacy. Here we employ a multi-parametric array of five translatable MRI techniques to characterise the in vivo pathophysiological phenotype of the rTg4510 mouse model of tauopathy (structural imaging, diffusion tensor imaging (DTI), arterial spin labelling (ASL), chemical exchange saturation transfer (CEST) and glucose CEST). Tau-induced pathological changes included grey matter atrophy, increased radial diffusivity in the white matter, decreased amide proton transfer and hyperperfusion. We demonstrate that the above markers unambiguously discriminate between the transgenic group and age-matched controls and provide a comprehensive profile of the multifaceted neuropathological processes underlying the rTg4510 model. Furthermore, we show that ASL and DTI techniques offer heightened sensitivity to processes believed to precede detectable structural changes and, as such, provides a platform for the study of disease mechanisms and therapeutic intervention.
Neurobiology of Aging | 2016
Holly Holmes; Niall Colgan; Ozama Ismail; Da Ma; Nick M. Powell; James M. O'Callaghan; Ian F. Harrison; Ross A. Johnson; Tracey K. Murray; Zeshan Ahmed; Morton Heggenes; Alice Fisher; Manuel Jorge Cardoso; Marc Modat; Simon Walker-Samuel; Elizabeth M. C. Fisher; Sebastien Ourselin; Michael J. O'Neill; Jack A. Wells; Emily C. Collins; Mark F. Lythgoe
Mouse models of Alzheimers disease have served as valuable tools for investigating pathogenic mechanisms relating to neurodegeneration, including tau-mediated and neurofibrillary tangle pathology—a major hallmark of the disease. In this work, we have used multiparametric magnetic resonance imaging (MRI) in a longitudinal study of neurodegeneration in the rTg4510 mouse model of tauopathy, a subset of which were treated with doxycycline at different time points to suppress the tau transgene. Using this paradigm, we investigated the sensitivity of multiparametric MRI to both the accumulation and suppression of pathologic tau. Tau-related atrophy was discernible from 5.5 months within the cortex and hippocampus. We observed markedly less atrophy in the treated rTg4510 mice, which was enhanced after doxycycline intervention from 3.5 months. We also observed differences in amide proton transfer, cerebral blood flow, and diffusion tensor imaging parameters in the rTg4510 mice, which were significantly less altered after doxycycline treatment. We propose that these non-invasive MRI techniques offer insight into pathologic mechanisms underpinning Alzheimers disease that may be important when evaluating emerging therapeutics targeting one of more of these processes.
NeuroImage | 2017
James M. O'Callaghan; Holly Holmes; Nick M. Powell; Jack A. Wells; Ozama Ismail; Ian F. Harrison; Bernard Siow; Ross A. Johnson; Zeshan Ahmed; Alice Fisher; Soraya Meftah; Michael J. O'Neill; Tracey K. Murray; Emily C. Collins; K Shmueli; Mark F. Lythgoe
Abstract Alzheimers disease is connected to a number of other neurodegenerative conditions, known collectively as ‘tauopathies’, by the presence of aggregated tau protein in the brain. Neuroinflammation and oxidative stress in AD are associated with tau pathology and both the breakdown of axonal sheaths in white matter tracts and excess iron accumulation grey matter brain regions. Despite the identification of myelin and iron concentration as major sources of contrast in quantitative susceptibility maps of the brain, the sensitivity of this technique to tau pathology has yet to be explored. In this study, we perform Quantitative Susceptibility Mapping (QSM) and T2* mapping in the rTg4510, a mouse model of tauopathy, both in vivo and ex vivo. Significant correlations were observed between histological measures of myelin content and both mean regional magnetic susceptibility and T2* values. These results suggest that magnetic susceptibility is sensitive to tissue myelin concentrations across different regions of the brain. Differences in magnetic susceptibility were detected in the corpus callosum, striatum, hippocampus and thalamus of the rTg4510 mice relative to wild type controls. The concentration of neurofibrillary tangles was found to be low to intermediate in these brain regions indicating that QSM may be a useful biomarker for early stage detection of tau pathology in neurodegenerative diseases. HighlightsThe rTg4510 is a mouse model of tauopathy.We applied QSM and T2* Mapping MRI techniques to the rTg4510 in vivo and ex vivo.QSM demonstrated sensitivity to regions of low and intermediate tau burden.QSM may hold potential as a non‐invasive early biomarker of tau pathology.
Frontiers in Neuroinformatics | 2017
Holly Holmes; Nick M. Powell; Da Ma; Ozama Ismail; Ian F. Harrison; Jack A. Wells; Niall Colgan; James M. O'Callaghan; Ross A. Johnson; Tracey K. Murray; Zeshan Ahmed; Morten Heggenes; Alice Fisher; M. Jorge Cardoso; Marc Modat; Michael J. O'Neill; Emily C. Collins; Elizabeth M. C. Fisher; Sebastien Ourselin; Mark F. Lythgoe
With increasingly large numbers of mouse models of human disease dedicated to MRI studies, compromises between in vivo and ex vivo MRI must be fully understood in order to inform the choice of imaging methodology. We investigate the application of high resolution in vivo and ex vivo MRI, in combination with tensor-based morphometry (TBM), to uncover morphological differences in the rTg4510 mouse model of tauopathy. The rTg4510 mouse also offers a novel paradigm by which the overexpression of mutant tau can be regulated by the administration of doxycycline, providing us with a platform on which to investigate more subtle alterations in morphology with morphometry. Both in vivo and ex vivo MRI allowed the detection of widespread bilateral patterns of atrophy in the rTg4510 mouse brain relative to wild-type controls. Regions of volume loss aligned with neuronal loss and pathological tau accumulation demonstrated by immunohistochemistry. When we sought to investigate more subtle structural alterations in the rTg4510 mice relative to a subset of doxycycline-treated rTg4510 mice, ex vivo imaging enabled the detection of more regions of morphological brain changes. The disadvantages of ex vivo MRI may however mitigate this increase in sensitivity: we observed a 10% global shrinkage in brain volume of the post-mortem tissues due to formalin fixation, which was most notable in the cerebellum and olfactory bulbs. However, many central brain regions were not adversely affected by the fixation protocol, perhaps due to our “in-skull” preparation. The disparity between our TBM findings from in vivo and ex vivo MRI underlines the importance of appropriate study design, given the trade-off between these two imaging approaches. We support the utility of in vivo MRI for morphological phenotyping of mouse models of disease; however, for subtler phenotypes, ex vivo offers enhanced sensitivity to discrete morphological changes.
Alzheimers & Dementia | 2016
Justin T. Hole; Margaret M. Racke; John Tzaferis; Feng Liu; Herold Oluoch; Zeshan Ahmed; Alice Fisher; Wesley Anderson; Philip Iversent; Celedon Gonzales; Zhixiang Yang; Leonard N. Boggs; Scott A. Monk; Dustin J. Mergott; Ying Yt. Yang; Jirong Lu; Michael C. Irizarry; John R. Sims; Patrick C. May; Michael Hutton; Christer Nordstedt; Ronald B. DeMattos
lowed. Results:High antibody responses were found in both species. In the rabbit, 277.16 118.4 mg/ml plasmaweremeasured after 5 immunizations with no significant differences between the dose groups. Antibody levels declined slightly to 246.66 109.5 mg/ml after a resting period of two months. Low levels of IFNg and IL-17 secreting splenocytes were found in the ELISPOTassays from rabbit splenocytes. Rhesusmonkeys reachedmean antibody levels of 114.2 6 41.67 mg/ml plasma after five immunizations. The isotype profile was high on IgG4 antibodies, indicative of a Th2 immune response. After three immunizations, no IL-17 or IFNg producing cells were found in ELISPOT assays from PBMCs. Conclusions: DNA Ab42 immunization leads to high antibody titers in large mammals, and is likely to produce high antibody levels and a safe (Th2 biased) immune response in humans as well. supported by NIA/NIH P30AG12300-21, Zale Foundation, Rudman Foundation, AWARE, Presbyterian Village North, Freiberger, and Denker Family Funds
Frontiers in Neuroscience | 2017
Niall Colgan; Balaji Ganeshan; Ian F. Harrison; Ozama Ismail; Holly Holmes; Jack A. Wells; Nick M. Powell; James M. O'Callaghan; Michael J. O'Neill; Tracey K. Murray; Zeshan Ahmed; Emily C. Collins; Ross A. Johnson; Ashley M. Groves; Mark F. Lythgoe
Background: Non-invasive characterization of the pathological features of Alzheimers disease (AD) could enhance patient management and the development of therapeutic strategies. Magnetic resonance imaging texture analysis (MRTA) has been used previously to extract texture descriptors from structural clinical scans in AD to determine cerebral tissue heterogeneity. In this study, we examined the potential of MRTA to specifically identify tau pathology in an AD mouse model and compared the MRTA metrics to histological measures of tau burden. Methods: MRTA was applied to T2 weighted high-resolution MR images of nine 8.5-month-old rTg4510 tau pathology (TG) mice and 16 litter matched wild-type (WT) mice. MRTA comprised of the filtration-histogram technique, where the filtration step extracted and enhanced features of different sizes (fine, medium, and coarse texture scales), followed by quantification of texture using histogram analysis (mean gray level intensity, mean intensity, entropy, uniformity, skewness, standard-deviation, and kurtosis). MRTA was applied to manually segmented regions of interest (ROI) drawn within the cortex, hippocampus, and thalamus regions and the level of tau burden was assessed in equivalent regions using histology. Results: Texture parameters were markedly different between WT and TG in the cortex (E, p < 0.01, K, p < 0.01), the hippocampus (K, p < 0.05) and in the thalamus (K, p < 0.01). In addition, we observed significant correlations between histological measurements of tau burden and kurtosis in the cortex, hippocampus and thalamus. Conclusions: MRTA successfully differentiated WT and TG in brain regions with varying degrees of tau pathology (cortex, hippocampus, and thalamus) based on T2 weighted MR images. Furthermore, the kurtosis measurement correlated with histological measures of tau burden. This initial study indicates that MRTA may have a role in the early diagnosis of AD and the assessment of tau pathology using routinely acquired structural MR images.
Alzheimers & Dementia | 2016
Zeshan Ahmed; Jane Cooper; Alice Fisher; Kate Jackson; Tracey K. Murray; Annalisa Cavallini; Suchira Bose; Michel Goedert; Michael Hutton; Michael J. O'Neill
classified older individuals into disease stages using deciles of whole-brain PIB distribution volume ratio (DVR), assuming that those with lower whole-brain DVRs are at earlier stages. We identified epicenters by finding ROIs that met the following criteria: (1) the PIB DVR in the ROI is greater than the average of its neighbors on the MST, (2) in the successive stage average PIB DVR in the neighbors increases, and (3) the ROI is not near another epicenter on the MST. Results:At all stages of PIB progression we found a strong significant positive correlation of regional PIB DVR with the average PIB DVR in neighboring regions at the successive stage. Moreover, with each 5 or 10 percentile increase in whole brain DVR we found a progressively stronger positive correlation of regional PIB DVRwith increased PIB DVR in neighboring regions relative to the initial stage. Finally, we identified distinct epicenters of PIB accumulation in the left posterior cingulate, left rostral anterior cingulate, left putamen, right pars opercularis, right suparmarginal, right lateral orbitofrontal, and right pericalcarine cortex which this approach identified as arising independently from one another. Conclusions:PIB appears to arise from multiple epicenters based on patterns of normal brain connectivity.
Alzheimers & Dementia | 2016
Suchira Bose; Annalisa Cavallini; Caroline Kerridge; Jane Cooper; Samuel Jackson; Alessia Landi; Claire V. Cella; Benjamin Falcon; Tracey K. Murray; Zeshan Ahmed; Michel Goedert; Michael Hutton; Michael J. O'Neill
Background:The neurofibrillary tangle is a pathological hallmark of Alzheimer’s disease (AD) and primarily consists of hyperphosphorylated tau protein (pTau). pTau first appears in the entorhinal cortex in the presymptomatic stage, then gradually disseminates to the hippocampal region around the onset of clinical symptoms of AD. Halting this tau spread in the asympomatic stage is a promising therapeutic approach for AD. The exosome is a small vesicle of 50-100 nm in diameter, enriched in ceramide, and is suggested to contain neuropathogenic proteins, such as prion, a-synuclein, and recently tau proteins. A growing body of evidence suggests that microglia contribute to tauopathy-related pathogenesis in both human and animal models. We hypothesize that microglia transduce tau aggregates into nearby neuronal cells via exosomal secretion, and that inhibition of the exosome synthesis or secretory pathway reduces tau dissemination. Methods: Adeno-associated virus serotype 6 expressing FTDP-17-linked mutation of tau protein was stereotaxically injected into the entorhinal cortical region of C57BL/6 mice, and the animals were sacrificed at 7 and 28 days post injection. The brain specimens were examined for tau accumulation in the hippocampal region. The animals were also systemically treated with specific inhibitors of neutral sphingomyelinase-2 to block exosome synthesis, or colony stimulating factor 1 receptor (CSF1R) to deplete microglia. Results:We found that human tau propagate from entorhinal cortical neurons to dentate granular cells after AAV injection, and that this propagation is sensitive to the inhibition of exosome synthesis or microglial depletion. We also found that tau-containing exosomes isolated from microglia efficiently transduce tau protein to neurons in vitro and in vivo. Finally, these results were reproduced in P301S tau mice (PS19) treated with these compounds. Conclusions: These results demonstrate that exosome secretion from microglia play a significant role in propagation of tau protein from entorhinal cortex to hippocampal neurons. Our findings could lead to an entirely novel paradigm for delaying the progression of disease in AD and other tauopathies such as frontotemporal dementia and chronic traumatic encephalopathy.